Shorter spell of endocrine therapy 'sufficient' for breast cancer

Results are strong evidence against routine extended use in postmenopausal women with hormone-receptor positive disease, expert says

Two years of extra therapy with an adjuvant aromatase inhibitor is sufficient for women with hormone-receptor-positive breast cancer, according to trial results.

postmenopausal woman against pink background wearing ribbon

The finding should change clinical practice, with women needing only a total of seven years’ endocrine therapy rather than 10, the authors say.

In the trial, dubbed ABCSG-16/SALSA, almost 3500 postmenopausal volunteers from 75 Austrian cancer clinics had already received